Drugs / YAP101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06831825 | Apr 2025 → Dec 2026 expected | symptomatic heart failure | YAP Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YAP101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06831825 ↗ |
| Known as | AAV9-Sav-shRNA | “YAP101 (AAV9-Sav-shRNA)” NCT06831825 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “YAP101, a novel gene therapy, delivers adeno-associated virus” NCT06831825 ↗ |
| Route | Other | “one-time transendocardial injection of YAP101” NCT06831825 ↗ |